Insights from 2024 EHA Annual Meeting

Videos

EHA 2024 Insights: Sonrotoclax + Zanubrutinib in R/R CLL/SLL

By Insights from 2024 EHA Annual Meeting FEATURING Stephen S. Opat

51 views

July 3, 2024

Sonrotoclax & Zanubrutinib: Potency & FDA Approval

00:00

Phase 1 Study & Patient Baselines in R/R CLL/SLL

01:18

Safety, Efficacy & MRD Results at Varied Doses

03:19

Comments 0

Highlights of Recent Updates in CML: Impact on Practice

2024 ASCO® Annual Meeting Insights Hub

E. Atallah

46 views

EHA 2024 Insights: OMS906, a Novel MASP-3 Inhibitor, in PNH Patients…

Insights from 2024 EHA Annual Meeting

M. Griffin

35 views

Biological Highlights in CML From EHA

International CML Foundation

N. Cross

44 views

Clinical Highlights in CML From EHA

International CML Foundation

A. Hochhaus

42 views

Top 5 Impactful MPN Abstracts From Summer Conferences

Insights from 2024 EHA Annual Meeting

P. Bose

157 views

EHA 2024 Insights: Relationship Between Hemoglobin and QoL in Transf…

Insights from 2024 EHA Annual Meeting

E. Oliva

27 views

EHA 2024 Insights: Real-World Data From R/R BPDCN Treated With Tagra…

Insights from 2024 EHA Annual Meeting

E. Angelucci

206 views

EHA 2024 Insights: Limited Stage HL - Current SOC, Future Directions…

Insights from 2024 EHA Annual Meeting

S. Park

58 views

EHA 2024 Insights: Sonrotoclax and Zanubrutinib Combination Therapy …

Insights from 2024 EHA Annual Meeting

C. Tam

21 views

EHA 2024 Insights: Golcadomide, an Oral CELMoD, + R-CHOP in Patients…

Insights from 2024 EHA Annual Meeting

M. Hoffmann

32 views

AML, MDS, and CML Highlights & Key Takeaways From ASCO®/EHA 2024

Insights from 2024 EHA Annual Meeting

T. Badar

711 views

EHA 2024 Insights: Treatment of Advanced Stage, High-Risk Hodgkin's …

Insights from 2024 EHA Annual Meeting

M. Salamoon

157 views

EHA 2024 Insights: Intrathecal Rituximab + Dex for Refractory Sanctu…

Insights from 2024 EHA Annual Meeting

M. Salamoon

121 views

EHA 2024 Insights: Zanubrutinib vs. Acalabrutinib in B-cell Malignan…

Insights from 2024 EHA Annual Meeting

T. Munir

73 views

EHA 2024 Insights: Low-Molecular-Weight Heparin and VTE in Newly Dia…

Insights from 2024 EHA Annual Meeting

M. Lauw

82 views

EHA 2024 Insights: Results by Cytogenetic Risk From PERSEUS - Dara-V…

Insights from 2024 EHA Annual Meeting

M. Dimopoulos

71 views

EHA 2024 Insights: Impact of Anemia on Clinical Outcomes in MF Patie…

Insights from 2024 EHA Annual Meeting

H. Kathrin Al-Ali

99 views

EHA 2024 Insights: Sonrotoclax + Zanubrutinib in R/R CLL/SLL

Insights from 2024 EHA Annual Meeting

S. Opat

51 views

EHA 2024 Insights: Infectious Complications in BCMA- and GPRC5D-Targ…

Insights from 2024 EHA Annual Meeting

J. Mersi

28 views

EHA 2024 Insights: FLAG-GO vs. FLAG-IDA in Untreated Core Binding Fa…

Insights from 2024 EHA Annual Meeting

G. Borthakur

147 views

EHA 2024 Insights: PROs After Epcoritamab in R/R Follicular Lymphoma

Insights from 2024 EHA Annual Meeting

W. Jurczak

33 views

EHA 2024 Insights: Updated Trends in Real-World Outpatient Administr…

Insights from 2024 EHA Annual Meeting

R. Bansal

36 views

EHA 2024 Insights: Axicabtagene Ciloleucel in R/R Primary Mediastina…

Insights from 2024 EHA Annual Meeting

J. Galtier

18 views

EHA 2024 Insights: Sequential Administration of Bispecific Antibodie…

Insights from 2024 EHA Annual Meeting

D. Fandrei

117 views

EHA 2024 Insights: SYMPATICO Study - Ibrutinib + Venetoclax in MCL W…

Insights from 2024 EHA Annual Meeting

W. Jurczak

32 views

EHA 2024 Insights: SEQUOIA Trial Arm D - Zanubrutinib + Venetoclax f…

Insights from 2024 EHA Annual Meeting

P. Ghia

158 views

EHA 2024 Insights: The Impact of TP53 Mutation Burden on Risk & Trea…

Insights from 2024 EHA Annual Meeting

M. Salamoon

173 views

EHA 2024 Insights: CD20-Targeted CAR-T Therapy for BTKi-Refractory W…

Insights from 2024 EHA Annual Meeting

M. Shadman

61 views

EHA 2024 Insights: Advantages of Using Venetoclax-Based Therapy in H…

Insights from 2024 EHA Annual Meeting

C. Coombs

82 views

EHA 2024 Insights: QuANTUM-First Trial - Newly Diagnosed FLT3-ITD+ A…

Insights from 2024 EHA Annual Meeting

E. Oliva

127 views

EHA 2024 Insights: Final 5-Year Results of Olutasidenib for Mutated …

Insights from 2024 EHA Annual Meeting

J. Cortés

25 views

EHA 2024 Insights: REVIVE Study - Updated Long-Term Results of Hepci…

Insights from 2024 EHA Annual Meeting

K. Pettit

18 views

EHA 2024 Insights: Daratumumab for iTTP

Insights from 2024 EHA Annual Meeting

J. Weisinger

138 views

Highlights in Plasma Cell Disorders From ASCO® and EHA

Insights from 2024 EHA Annual Meeting

S. Al Hadidi

466 views

EHA 2024 Insights: AML Highlights - Focus on Menin Inhibitors

Insights from 2024 EHA Annual Meeting

J. Zeidner

65 views

EHA 2024 Insights: FLAG-IDA + Venetoclax in Newly Diagnosed or R/R A…

Insights from 2024 EHA Annual Meeting

W. Jen

236 views

Responder Analysis From the PhALLCON Trial: Ponatinib vs. Imatinib i…

Insights from 2024 EHA Annual Meeting

J. Ribera

105 views

Experts Discuss Highlights and Key Takeaways in CLL From ASCO® and E…

2024 ASCO® Annual Meeting Insights Hub

K. Rogers, J. Woyach

306 views

EHA 2024 Insights: TRANSCEND NHL 001 Study - Liso-Cel in R/R MCL - A…

Insights from 2024 EHA Annual Meeting

M. Kamdar

52 views

EHA 2024 Insights: PERSEUS Trial MRD Analysis: Dara + VRd in Transpl…

Insights from 2024 EHA Annual Meeting

P. Sonneveld

95 views

EHA 2024 Insights: QUAZAR AML-001 - Oral Azacitidine Maintenance in …

Insights from 2024 EHA Annual Meeting

M. Teresa Voso

87 views

Login

Login

Join VuMedi